Why the study?
Does oral pleconaril reduce the duration and severity of illness in adults with colds due to picornaviruses?
Does oral pleconaril reduce the duration and severity of illness in adults with colds due to picornaviruses?
Early oral pleconaril treatment significantly reduces the duration and severity of colds due to picornaviruses in adults, though it is associated with mild gastrointestinal side effects and CYP3A induction.
Answers are grounded in this paper and cite their sources.
Supports pleconaril for picornavirus colds despite mild GI effects and CYP3A induction; confirms RCT efficacy and extends antiviral options in adults.
The novel capsid-binding antiviral pleconaril inhibits in vitro replication of most rhinoviruses and enteroviruses. Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials. Among 1363 picornavirus-infected participants (65%) in the studies combined, the median time to alleviation of illness was 1 day shorter for pleconaril recipients than for placebo recipients (P<.001). Cold symptom scores and frequency of picornavirus cultured from nasal mucus specimens were lower among pleconaril recipients by day 2 of treatment. No treatment effects were seen in those without picornavirus infection. Pleconaril was associated with a higher incidence of nausea (6% vs. 4%) and diarrhea (9% vs. 7%) and with small increases in mean serum cholesterol levels and platelet counts, compared with baseline measurements. A subsequent 6-week prophylaxis study found that pleconaril induces cytochrome P-450 3A enzymes, which metabolize a variety of drugs, including ethinyl estradiol. Early pleconaril treatment was well tolerated and significantly reduced the duration and severity of colds due to picornaviruses in adults.
No takes yet. Share an insight, caveat, or question.
Hayden et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: